1. Kumar-Sinha C, Chinnaiyan AM: Precision oncology in the age of integrative genomics. Nat Biotechnol 2018, 36:46-60.
2. Ke X, Shen L: Molecular targeted therapy of cancer: The progress and future prospect. Frontiers in Laboratory Medicine 2017, 1:69-75.
3. Redman MW, Allegra CJ: The Master Protocol Concept. Semin Oncol 2015, 42:724-730.
4. Hirakawa A, Asano J, Sato H, Teramukai S: Master protocol trials in oncology: Review and new trial designs. Contemp Clin Trials Commun 2018, 12:1-8.
5. Renfro LA, Sargent DJ: Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017, 28:34-43.
6. Woodcock J, LaVange LM: Master protocols to study multiple therapies, multiple diseases, or both. New England Journal of Medicine 2017, 377:62-70.
7. Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R: Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials 2017, 14:451-461.
8. Sydes MR, Parmar MKB, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P: Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009, 10:39.
9. Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, et al: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: Directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology 2018, 29:1235-1248.
10. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, et al: Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018, 392:2353-2366.
11. Berry SM, Connor JT, Lewis RJ: The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015, 313:1619-1620.
12. Saville BR, Berry SM: Efficiencies of platform clinical trials: A vision of the future. Clin Trials 2016, 13:358-366.
13. Lam VK, Papadimitrakopoulou V: Master protocols in lung cancer: experience from Lung Master Protocol. Curr Opin Oncol 2018, 30:92-97.
14. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 2009, 151:264-269.
15. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry (Draft Guidance) [https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621817.pdf]
16. Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A: Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clinical Cancer Research 2008, 14:2717-2725.
17. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005, 23:866-873.
18. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, et al: Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU international 2009, 103:464-469.
19. Sydes MR, Parmar MKB, Mason MD, Clarke NW, Amos C, Anderson J, de Bono J, Dearnaley DP, Dwyer J, Green C, et al: Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 2012, 13:168.
20. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, et al: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. The New England journal of medicine 2017, 377:338-351.
21. James N, De Bono J, Spears MR, Clarke NW, Mason MD, Dearnaley D, Ritchie AWS, Russell M, Gilson C, Jones R, et al: Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). Annals of Oncology 2017, 28:v620.
22. James ND, De Bono JS, Spears MR, Clarke N, Mason MD, Dearnaley DP, Ritchie AWS, Russell JM, Gilson C, Jones RJ, et al: Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology 2017, 35.
23. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AWS, Russell JM, et al: Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. The Lancet Oncology 2012, 13:549-558.
24. James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Dwyer J, Jovic G, Russell JM, Thalmann G, Parmar MKB: Celecoxib plus hormone therapy vs hormone therapy alone for hormone-sensitive prostate cancer: First results from the STAMPEDE randomised controlled trial (MRC PR08). European Journal of Cancer 2011, 47:11.
25. Mason Md CNWJNDDDPSMRRAWSAGCWJR: Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of clinical oncology 2017, 35:1530.
26. Sydes MR, James ND, Mason MD, Clarke NW, Amos C, Anderson J, De Bono J, Dearnaley DP, Dwyer J, Jovic G, et al: Flexible trial design in practice - Dropping and adding arms in STAMPEDE: A multi-arm multi-stage randomised controlled trial. Trials 2011, 12.
27. Sydes MR, Mason MD, Spears MR, Clarke NW, Dearnaley D, Ritchie AWS, Russell M, Gilson C, Jones R, De Bono J, et al: PR Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476). Annals of Oncology 2017, 28:v619.
28. Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, et al: Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015, 33:1000-1007.
29. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, et al: Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol 2018, 36:536-542.
30. Derhaschnig U, Gilbert J, Jager U, Bohmig G, Stingl G, Jilma B: Combined integrated protocol/basket trial design for a first-in-human trial. Orphanet journal of rare diseases 2016, 11:134.
31. Muhlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schorgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S, Bohmig GA: Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial. Transplantation 2017, 101:2410-2418.
32. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ: I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009, 86:97-100.
33. Berry DA, Graves T, Connor J, Alexander B, Cloughesy T, Barker A, Berry SM: Adaptively randomized seamless-phase multiarm platform trial: Glioblastoma Multiforme Adaptive Global Innovative Learning Environment (GBM AGILE). Cancer Research 2017, 77.
34. Forero A, Yee D, Buxton MB, Symmans WF, Chien AJ, Boughey JC, Elias AD, DeMichele A, Moulder S, Minton S, et al: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial. Cancer Research 2017, 77.
35. Nanda R, Liu MC, Yau C, Asare S, Hylton N, Van't Veer L, Perlmutter J, Wallace AM, Chien AJ, Forero-Torres A, et al: Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Journal of Clinical Oncology 2017, 35.
36. Paoloni M, Lyandres J, Buxton MB, Berry DA, Esserman LJ, DeMichele A, Yee D: A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL. Cancer Research 2017, 77.
37. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, et al: Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The New England journal of medicine 2016, 375:23-34.
38. Yee D, Paoloni M, Van't Veer L, Sanil A, Yau C, Forero A, Chien AJ, Wallace AM, Moulder S, Albain KS, et al: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the ISPY 2 trial. Cancer Research 2017, 77.
39. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, et al: Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med 2016, 375:11-22.
40. Lih C-J, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V: Analytical validation and application of a targeted next-generation sequencing mutation-detection assay for use in treatment assignment in the NCI-MPACT trial. The Journal of Molecular Diagnostics 2016, 18:51-67.
41. Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, et al: Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 2018, 93:E49-E52.
42. Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, Corey GR, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW: A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response. Clinical trials (London, England) 2016, 13:22-30.
43. Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, et al: The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017, 13:8-19.
44. Wen PY, Alfred Yung WK, David Adelson P, Alexander BM, Alper J, Arnold MM, Arons DF, Ashley DN, Ba S, Barker AD, et al: Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clinical Cancer Research 2018, 24:737-743.
45. Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, et al: Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res 2018, 24:737-743.
46. Diamond EL, Subbiah V, Craig Lockhart A, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, et al: Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncology 2018, 4:384-388.
47. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al: Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015, 373:726-736.
48. De Benedetti F, Anton J, Gattorno M, Lachmann H, Kone-Paut I, Ozen S, Frenkel J, Simon A, Zeft A, Ben-Chetrit E, et al: Efficacy and safety of Canakinumab in patients with periodic fever syndromes (colchicine-resistant fmf, hids/mkd and traps): Results from a phase 3, pivotal, umbrella trial. Pediatric Rheumatology 2017, 15.
49. De Benedetti F, Anton J, Gattorno M, Lachmann H, Kone-Paut I, Ozen S, Frenkel J, Simon A, Zeft A, Ben-Chetrit E, et al: Pharmacokinetics and pharmacodynamics of canakinumab in patients with periodic fever syndromes (colchicine-resistant FMF, HIDS/MKD and TRAPS): Results from a phase III pivotal umbrella trial. Pediatric Rheumatology 2017, 15.
50. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Kone-Paut I, Lachmann HJ, Ozen S, Simon A, et al: Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018, 378:1908-1919.
51. Butler CC, Coenen S, Saville BR, Cook J, van der Velden A, Homes J, de Jong M, Little P, Goossens H, Beutels P, et al: A trial like ALIC4E: Why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness? ERJ Open Research 2018, 4:00046-02018.